摘要
<正>Survival rates after cardiac arrest have not changed substantially over the past 5 decades.Postcardiac arrest(CA) syndrome(PCAS) is the primary reason for the high mortality rate after successful restoration of spontaneous circulation(ROSC).Intravenous administration of Shenfu Injection(参附注射液,SFI) may attenuate post-CA myocardial dysfunction and cerebral injury,inhibit systemic ischemia/reperfusion responses, and treat underlying diseases.In this article,we reviewed the therapeutic effects of SFI in PCAS.SFI might be useful in the treatment of PCAS,incorporating the multi-link and multi-target advantages of Chinese medicine into PCAS management.Further experimental and clinical research to verify the therapeutic effects of SFI in PCAS is required.